Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab

被引：0

作者：

Gudesblatt, Mark ^{[1
,2
]}

Zarif, Myassar ^{[2
]}

Bumstead, Barbara ^{[2
]}

Buhse, Marijean ^{[2
]}

Kaczmarek, Olivia ^{[2
]}

Li, Hanyue ^{[3
]}

Sun, Zhaonan ^{[3
]}

Scott, Nicole ^{[3
]}

Mendoza, Jason P. ^{[3
]}

Avila, Robin L. ^{[3
]}

机构：

[1] Langone South Shore Neurol Associates, 77 Medford Ave, Patchogue, NY 11772 USA

[2] NYU Langone South Shore Neurol Associates PC, Patchogue, NY USA

[3] Biogen, Cambridge, MA USA

来源：

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL | 2023年 / 9卷 / 04期

关键词：

Multiple sclerosis; natalizumab; COVID-19; vaccine;

D O I：

10.1177/20552173231218117

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The immunomodulatory effects of disease-modifying therapies for multiple sclerosis might affect the immune response to vaccines for severe acute respiratory syndrome coronavirus 2. We analyzed the severe acute respiratory syndrome coronavirus 2-specific antibody response and lymphocyte profile before and after Ad26.COV2.S (Johnson & Johnson) vaccination in natalizumab-treated patients with multiple sclerosis. There was a 72-fold increase in mean anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G levels 4 weeks after vaccination and a 137-fold increase after 6 months. Other immune signals were within normal ranges. Natalizumab-treated patients with multiple sclerosis had a robust immune response to Ad26.COV2.S vaccine, and other immune signals were not significantly affected.

引用

页数：5

共 13 条

[1] Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study [J].

Achiron, Anat ;

Mandel, Mathilda ;

Dreyer-Alster, Sapir ;

Harari, Gil ;

Dolev, Mark ;

Menascu, Shay ;

Magalashvili, David ;

Flechter, Shlomo ;

Givon, Uri ;

Guber, Diana ;

Sonis, Polina ;

Zilkha-Falb, Rina ;

Gurevich, Michael .

JOURNAL OF NEUROIMMUNOLOGY, 2021, 361

[2]

[Anonymous], WHO COVID-19 dashboard, COVID-19 vaccination, World data

[3] Effects of MS disease-modifying therapies on responses to vaccinations: A review [J].

Ciotti, John Robert ;

Valtcheva, Manouela V. ;

Cross, Anne Haney .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 45

[4] Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions [J].

Cohen, Jeffrey A. ;

Bermel, Robert A. ;

Grossman, Cynthia, I ;

Hersh, Carrie M. ;

Hyland, Megan ;

Mowry, Ellen M. ;

Naismith, Robert ;

Naylor, Maria L. ;

Nicholas, Jacqueline ;

Rajbhandar, Rajani ;

Singh, Carol M. ;

Tintore, Mar ;

Zabalza, Ana ;

Ziemssen, Tjalf ;

Williams, James R. ;

Montalban, Xavier .

MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (07) :1131-1137

[5]

Gadani SP., EBioMedicine, V73, P10363

[6]

Health S., Laboratory Test Catalog. CD20 and CD19

[7] SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates [J].

Kyriakidis, Nikolaos C. ;

Lopez-Cortes, Andres ;

Vasconez Gonzalez, Eduardo ;

Barreto Grimaldos, Alejandra ;

Ortiz Prado, Esteban .

NPJ VACCINES, 2021, 6 (01)

[8] Disease and healthcare burden of COVID-19 in the United States [J].

Miller, Ian F. ;

Becker, Alexander D. ;

Grenfell, Bryan T. ;

Metcalf, C. Jessica E. .

NATURE MEDICINE, 2020, 26 (08) :1212-+

[9] Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies [J].

Ozakbas, Serkan ;

Baba, Cavid ;

Dogan, Yavuz ;

Cevik, Sumeyye ;

Ozcelik, Sinem ;

Kaya, Ergi .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58

[10]

Padilla O., 2022, Blood Tests: Normal Values

← 1 2 →